Xiaojin Shi

3.0k citations
91 papers · 2.2k indexed · 1 hit paper · h-index 26
Topics
Lung Cancer Treatments and Mutations (10 papers)Pharmacological Effects and Toxicity Studies (8 papers)Colorectal Cancer Treatments and Studies (7 papers)
Journals
Journal of Clinical OncologySHILAP Revista de lepidopterologíaCancer Research
Partner nations
ChinaUnited StatesJapan

In The Last Decade

Xiaojin Shi

82 papers receiving 2.2k citations

Hit Papers

Durvalumab With or Without Tremelimumab in Combination Wi...2022202620232024202250100150200

Peers

Xiaojin Shi
Comparison fields: 5 of 130
  • Oncology 1.0k
  • Pulmonary and Respiratory Medicine 743
  • Molecular Biology 716
  • Cancer Research 236
  • Surgery 174
Replace Takashi Kobayashi with:
Takashi Kobayashi Japan
Ronald Lieberman United States
Antoinette Lemoine France
Balram Chowbay Singapore
Katsuya Endo Japan
Patrick Caron Canada
Michel Pétein Belgium
Haibo Wang China
Stacy S. Shord United States
Carmen Gómez‐Guerrero Spain
Xiaojin Shi relative to Takashi Kobayashi Japan Takashi Kobayashi's profile →
Citations per field
00.5×1.5×1.9×
Takashi Kobayashi · 1×
Citations per year

Countries citing papers authored by Xiaojin Shi

Since Specialization
Citations

This map shows the geographic impact of Xiaojin Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaojin Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaojin Shi more than expected).

Fields of papers citing papers by Xiaojin Shi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaojin Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaojin Shi. The network helps show where Xiaojin Shi may publish in the future.

Co-authorship network of co-authors of Xiaojin Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaojin Shi. A scholar is included among the top collaborators of Xiaojin Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaojin Shi. Xiaojin Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 7
3 0
4 2
5 0
6 8
7 1
8 0
9 1
10 3
11 11
12 4
13 1
14 16
15
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Studybreakdown →
238
16 12
17 33
18
Simultaneous separation and determination of zonisamide,phenytoin carbamazepine and carbamazepine 10,11-epoxide in human plasma using isocratic reversed-phase HPLC
1
19
Determination of Ezetimibe and Total Ezetimibe in Human Plasma and Its Pharmacokinetics
1
20
Study on Bioequivalence of Risperidone Tablets
1

About Xiaojin Shi

Xiaojin Shi is a scholar working on Transplantation, Oncology and Pharmacology, having authored 91 papers that have together received 2.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (10 papers), Pharmacological Effects and Toxicity Studies (8 papers) and Colorectal Cancer Treatments and Studies (7 papers). The work is most often cited by research in Transplantation (105 citations), Oncology (1.0k citations) and Pulmonary and Respiratory Medicine (743 citations). Xiaojin Shi has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Mingkang Zhong, Zheng Jiao, Tony Mok, Zhongdong Li, Qunyi Li, Liyuan Li, Zhao Wang, Yun Shi, Myung‐Ju Ahn and Santiago Ponce. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026